JP2005519849A5 - - Google Patents

Download PDF

Info

Publication number
JP2005519849A5
JP2005519849A5 JP2003504964A JP2003504964A JP2005519849A5 JP 2005519849 A5 JP2005519849 A5 JP 2005519849A5 JP 2003504964 A JP2003504964 A JP 2003504964A JP 2003504964 A JP2003504964 A JP 2003504964A JP 2005519849 A5 JP2005519849 A5 JP 2005519849A5
Authority
JP
Japan
Prior art keywords
imidazo
amine
naphthyridin
methylpropyl
irm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003504964A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005519849A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/018944 external-priority patent/WO2002102377A1/en
Publication of JP2005519849A publication Critical patent/JP2005519849A/ja
Publication of JP2005519849A5 publication Critical patent/JP2005519849A5/ja
Pending legal-status Critical Current

Links

JP2003504964A 2001-06-15 2002-06-14 歯周病の治療用免疫応答調節剤 Pending JP2005519849A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29876801P 2001-06-15 2001-06-15
PCT/US2002/018944 WO2002102377A1 (en) 2001-06-15 2002-06-14 Immune response modifiers for the treatment of periodontal disease

Publications (2)

Publication Number Publication Date
JP2005519849A JP2005519849A (ja) 2005-07-07
JP2005519849A5 true JP2005519849A5 (https=) 2005-12-22

Family

ID=23151928

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003504964A Pending JP2005519849A (ja) 2001-06-15 2002-06-14 歯周病の治療用免疫応答調節剤

Country Status (5)

Country Link
EP (1) EP1401437A1 (https=)
JP (1) JP2005519849A (https=)
CN (1) CN1523987A (https=)
CA (1) CA2449754A1 (https=)
WO (1) WO2002102377A1 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
RU2327460C2 (ru) 2001-11-29 2008-06-27 3М Инновейтив Пропертиз Компани Фармацевтические составы, содержащие иммуномодулятор
CA2365732A1 (en) 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
NZ534566A (en) 2002-02-22 2007-02-23 3M Innovative Properties Co Method of reducing and treating UVB-induced immunosuppression
MXPA04012199A (es) 2002-06-07 2005-02-25 3M Innovative Properties Co Imidazopiridinas sustituidas con eter.
NZ538812A (en) 2002-08-15 2009-02-28 3M Innovative Properties Co Immunostimulatory compositions and methods of stimulating an immune response
JP2006503068A (ja) 2002-09-26 2006-01-26 スリーエム イノベイティブ プロパティズ カンパニー １ｈ−イミダゾダイマー
MXPA05006740A (es) 2002-12-20 2005-10-05 3M Innovative Properties Co Imidazoquinolinas arilo-sustituidas.
AU2003300184B8 (en) 2002-12-30 2009-12-03 3M Innovative Properties Company Immunostimulatory combinations
JP2006517974A (ja) 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
US7485432B2 (en) 2003-02-27 2009-02-03 3M Innovative Properties Company Selective modulation of TLR-mediated biological activity
US8110582B2 (en) 2003-03-04 2012-02-07 3M Innovative Properties Company Prophylactic treatment of UV-induced epidermal neoplasia
AU2004220465A1 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
MXPA05009694A (es) 2003-03-13 2005-10-20 3M Innovative Properties Co Metodos para mejorar la calidad de la piel.
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
AU2004244962A1 (en) 2003-04-10 2004-12-16 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
WO2005020912A2 (en) 2003-08-25 2005-03-10 3M Innovative Properties Company Delivery of immune response modifier compounds
MXPA06002199A (es) 2003-08-27 2006-05-22 3M Innovative Properties Co Imidazoquinolinas sustituidas con grupos ariloxi o arilalquilenoxi.
JP2007504172A (ja) * 2003-09-02 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー 粘膜に関連した症状の処置に関する方法
CA2540541C (en) 2003-10-03 2012-03-27 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
WO2005051317A2 (en) 2003-11-25 2005-06-09 3M Innovative Properties Company Substituted imidazo ring systems and methods
US8940755B2 (en) 2003-12-02 2015-01-27 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
WO2006084251A2 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
US20100160368A1 (en) 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
WO2010080345A1 (en) 2008-12-19 2010-07-15 Graceway Pharmaceuticals, Llc Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
EA025993B1 (ru) 2009-07-13 2017-02-28 Медисис Фармасьютикал Корпорейшн Композиции с более низким содержанием имиквимода и короткие режимы дозирования для лечения остроконечных и перианальных бородавок
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
WO2019216438A1 (ja) * 2018-05-11 2019-11-14 株式会社セルテクノロジー 間葉系細胞の培養上清を含む歯周病治療剤
CN114616234B (zh) * 2019-02-07 2024-04-12 康威(广州)生物科技有限公司 磷咪唑并喹啉胺衍生物、及其药物组合物和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420168D0 (en) * 1994-10-06 1994-11-23 Boots Co Plc Therapeutic agents
US6541485B1 (en) * 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
MXPA03000388A (es) * 2000-07-13 2003-09-25 Alteon Inc Metodo para tratar enfermedades fibroticas u otras indicaciones ic.

Similar Documents

Publication Publication Date Title
JP2005519849A5 (https=)
US6825350B2 (en) Sulfonamide and sulfamide substituted imidazoquinolines and methods for the treatment of periodontal disease using these and other immune response modifiers
JP2008526752A5 (https=)
UA93496C2 (uk) Стерильний склад модифікатора імунної відповіді та способи одержання зазначеного складу
WO2003097641A3 (en) 1h-imidazo[4,5-c] quinoline derivatives in the treatment of protein kinase dependent diseases
MA30967B1 (fr) Sels et formes cristallines de 2-methyl-2-methyl-2-[4-(3-methyl-2-oxo-8-quinolein-3-yl-2,3-dihydro-imidazo[4,5-c]quinolein-1-yl) - phenyl]-propionitrile.
CA2449754A1 (en) Immune response modifiers for the treatment of periodontal disease
AU2003293460A1 (en) Novel application of biosensors for diagnosis and treatment of disease
JP2005528253A5 (https=)
TN2011000626A1 (en) 1h-imidazo[4,5-c]quinolinone derivatives
IL166489A (en) Oral dosage form in single-dose administration containing at least two layers for the administration and use of flipridone
EP1578385A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF INFLAMMATORY ENDURANCE DISEASES
EP1539251A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND THERAPY OF MEDICAL DISEASES WITH ANGIOGENESIS
JP2008533148A5 (https=)
EP1516049A4 (en) COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF LUNG CANCER
HUP0401569A2 (hu) Amlodipint és atorvastatint tartalmazó gyógyászati készítmények és eljárás az előállításukra
JP2021073257A5 (https=)
WO2005053719A3 (en) Compositions for the treatment of diseases of the oral cavity and upper respiratory tract
JP2004517824A5 (https=)
HUP0500028A2 (hu) Triaza-spiro[5.5]undekán-azármazék citokróm P450 izozim 3A4 inhibitorral és/vagy P-glikoprotein inhibitorral való kombinációját tartalmazó gyógyszer
EP1575993A4 (en) METHOD FOR TREATING PATIENTS AND IDENTIFYING THERAPEUTICS
JP2005524666A5 (https=)
JP2004502653A5 (https=)
WO2006079910A3 (en) 0-(3-piperidino-2hydroxypropyl)nicotinic amixodime for treating lesions in the oral cavity
Qi et al. Comparison of curative effect between different retrograde filling materials in young permanent molar root canal therapy